


Werner syndrome RecQ helicase-IN-4

Cat. No.:	HY-148741		
CAS No.:	2869954-53-8		
Molecular Formula:	C ₃₂ H ₃₃ F ₃ N ₈ O ₅		
Molecular Weight:	666.65		
Target:	DNA/RNA Synthesis		
Pathway:	Cell Cycle/DNA Damage		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (187.50 mM; Need ultrasonic)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.5000 mL	7.5002 mL	15.0004 mL
	5 mM	0.3000 mL	1.5000 mL	3.0001 mL
	10 mM	0.1500 mL	0.7500 mL	1.5000 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Werner syndrome RecQ helicase-IN-4 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC₅₀ value of 0.06 μM. Werner syndrome RecQ helicase-IN-4 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-4 shows anticancer activity^[1].

IC₅₀ & Target

IC₅₀: 0.06 μM (WRN)^[1]

In Vitro

Werner syndrome RecQ helicase-IN-4 (example 58) (0-10 μM; 8-20 days) shows antiproliferative activity with GI₅₀s of 0.07, >10 μM for SW48, DLD1 WRN-KO cells, respectively^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay^[1]

Cell Line:	SW48, DLD1 WRN-KO cells
Concentration:	0-10 μM

	Incubation Time:	8-20 days
	Result:	Showed antiproliferative activity with GI ₅₀ s of 0.07, >10 μM for SW48, DLD1 WRN-KO cells, respectively.
In Vivo	Werner syndrome RecQ helicase-IN-4 (240 mg/kg; daily for 18 days) shows anticancer activity in mouse ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Female Crl:NU(NCr)-Foxn1nu -Homozygous nude mice (SW48 xenografts cells) ^[1]
	Dosage:	240 mg/kg
	Administration:	P.o.; daily for 18 days
	Result:	Inhibited tumor growth.

REFERENCES

[1]. Vincent Bordas, et al. Triazolo-pyrimidine analogues for treating diseases connected to the inhibitor of werner syndrome recq helicase (wrn). WO2022249060A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA